Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Cytosorbents (CTSO) Other Non Operating Income (2016 - 2026)

Cytosorbents filings provide 11 years of Other Non Operating Income readings, the most recent being $193000.0 for Q4 2025.

  • On a quarterly basis, Other Non Operating Income rose 103.93% to $193000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $9.3 million, a 320.63% increase, with the full-year FY2025 number at $9.3 million, up 320.62% from a year prior.
  • Other Non Operating Income hit $193000.0 in Q4 2025 for Cytosorbents, up from -$64000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $6.2 million in Q2 2025 to a low of -$4.9 million in Q4 2024.
  • Median Other Non Operating Income over the past 5 years was -$278744.0 (2021), compared with a mean of $100952.8.
  • Biggest five-year swings in Other Non Operating Income: tumbled 1177.6% in 2022 and later surged 1235.66% in 2025.
  • Cytosorbents' Other Non Operating Income stood at -$493488.0 in 2021, then soared by 1015.53% to $4.5 million in 2022, then crashed by 40.61% to $2.7 million in 2023, then crashed by 282.8% to -$4.9 million in 2024, then surged by 103.93% to $193000.0 in 2025.
  • The last three reported values for Other Non Operating Income were $193000.0 (Q4 2025), -$64000.0 (Q3 2025), and $6.2 million (Q2 2025) per Business Quant data.